Search results with tag "Tolvaptan"
HIGHLIGHTS OF PRESCRIBING INFORMATION
www.otsuka-us.comJYNARQUE® (tolvaptan) JYNARQUE® (tolvaptan) 2 FULL PRESCRIBING INFORMATION WARNING: RISK OF SERIOUS LIVER INJURY JYNARQUE (tolvaptan) can cause serious and potentially fatal liver injury.
The effect of tolvaptan on autosomal dominant polycystic ...
www.pck.jpORIGINAL ARTICLE The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial
MANAGEMENT OF PAXLOVID DRUG-DRUG-INTERACTIONS
www.med.umich.edutolvaptan. Trazodone Reduce trazodone by 50%1 Voclosporin Do not use Paxlovid Vorapaxar Hold vorapaxar1 Warfarin Carefully monitor INR1. Page 5 of 6 Appendix A Preferred management of drug interactions of Paxlovid with calcineurin inhibitors and mTOR kinase inhibitors in
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eudominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease (see section 5.1). ... Tolvaptan may cause adverse reactions related to water loss such as …
FULL PRESCRIBING INFORMATION - accessdata.fda.gov
www.accessdata.fda.gov2 WARNING: RISK OF SERIOUS LIVER INJURY JYNARQUE (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported[see Warnings and Precautions (5.1)]. Measure ALT, AST and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation,
JYNARQUE® (tolvaptan) REMS PRESCRIBER ENROLLMENT …
jynarquerems.comJYNARQUE is available only through the JYNARQUE REMS, a restricted distribution program. Only prescribers, pharmacies, and patients enrolled in the program can …
ERA-EDTA recommendation on the use of …
era-edta.orgPress Office ERA-EDTA albersconcept | Dr. Bettina Albers | Jakobstraße 38 | D-99423 Weimar | Germany ERA-EDTA recommendation on the use of tolvaptan in polycystic kidney disease